CD46–ADC Reduces the Engraftment of Multiple Myeloma Patient-Derived Xenografts

SIMPLE SUMMARY: Multiple myeloma (MM) is incurable, implying that the disease cells are inherently resistant to current agents and inevitably lead to relapse. One strategy to improve the treatment paradigm is to pursue novel drug targets that are associated with relapsed disease. Towards this end, w...

Descripción completa

Detalles Bibliográficos
Autores principales: VanWyngarden, Michael J., Walker, Zachary J., Su, Yang, Perez de Acha, Olivia, Stevens, Brett M., Forsberg, Peter A., Mark, Tomer M., Matsui, William, Liu, Bin, Sherbenou, Daniel W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10670432/
https://www.ncbi.nlm.nih.gov/pubmed/38001595
http://dx.doi.org/10.3390/cancers15225335

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10670432/
https://www.ncbi.nlm.nih.gov/pubmed/38001595
http://dx.doi.org/10.3390/cancers15225335

Ejemplares similares